Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
04:33pm, Tuesday, 12'th Apr 2022
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
3 Soaring Pharma Stocks -- Can They Keep Climbing?
10:31am, Tuesday, 12'th Apr 2022 The Motley Fool
All three are near 52-week highs, but for how long?
3 Recession-Proof Dividend Stocks to Buy
02:38pm, Friday, 08'th Apr 2022
ABM Industries, Bristol-Myers and UGI are three examples of companies that saw earnings-per-share grow by high rates during the 2007 to 2009 period. All three companies have extensive dividend growth
Best Stocks for 2022: Bristol-Myers Squibb Isn't Done Growing
07:25am, Friday, 08'th Apr 2022
It's been a great year for Bristol-Myers Squibb this year, but it's not too late to jump in. BMY stock offers a respectable dividend.
BioPharma Giants Print Fresh All-Time Highs
03:48pm, Thursday, 07'th Apr 2022
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
Red-Hot Drug Stock Has Room to Run
02:01pm, Wednesday, 06'th Apr 2022
The shares of Bristol-Myers Squibb Co (NYSE:BMY) have been on a steady uptrend over the last several months, while boasting low implied volatility (IV).
Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi
01:33pm, Wednesday, 06'th Apr 2022
The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.
Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
01:33pm, Tuesday, 05'th Apr 2022
Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.
7 Biotech Stocks to Buy With Key Catalysts for April
06:59am, Tuesday, 05'th Apr 2022
Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel
This Healthcare ETF Has Compelling Prognosis
01:15pm, Monday, 04'th Apr 2022
Broadly speaking, the healthcare sector isn't on fire this year, but analysts are increasingly bullish on the group, citing attractive quality and valuation traits, among other factors. While the sect
7 No-Brainer Stocks to Buy for April
07:00am, Monday, 04'th Apr 2022
Start your stock scan with companies showing strong quant scores in value, growth and quality, then buy those with strong catalysts. The post 7 No-Brainer Stocks to Buy for April appeared first on Inv
2 Drugmakers Set for Explosive Revenue This Decade
06:00am, Sunday, 03'rd Apr 2022
They are selling much-needed products.
2 Warren Buffett Stocks to Buy Now and Hold Forever
10:53am, Thursday, 31'st Mar 2022
These two companies aren't going away anytime soon.
5 Charts That Show Why Bristol-Myers Squibb Is a No-Brainer Buy
10:15am, Wednesday, 30'th Mar 2022
The company gives investors plenty of reasons to buy and hold the stock for years.
Bristol Myers (BMY) Application for Opdivo With Chemo Validated
12:48pm, Tuesday, 29'th Mar 2022
Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.
